News

Until now, infants with malaria were typically treated with tablets meant for older children, adjusted for weight, the ...
Novartis ( NYSE: NVS) on Tuesday said that Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the ...
Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Tuesday that Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for ...
Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...
Coartem ® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...
CYP17A1 Inhibitors Market to Reach USD 1.35 Billion by 2025, Fueled by Advancements in Prostate Cancer Therapeutics The CYP17A1 inhibitors market is projected to attain USD 1,350 million by 2025, ...
What’s powering a $26.28 billion opportunity? The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood ...
LONDON, GREATER LONDON, UNITED KINGDOM, July 7, 2025 /EINPresswire.com/ -- Save 30% On All Global Market Reports With Code ONLINE30 – Stay Informed On Tariff Changes, Macroeconomic Trends, And More.
Most notably, at Novartis, she held several senior scientific ... having held Chief Medical Officer positions at Destiny Pharma and Polyneuron Pharmaceuticals AG. As Chief Medical and Development ...
Novartis on Tuesday said it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...